Aim to Reduce Movements in Tardive Dyskinesia
Public ClinicalTrials.gov record NCT02195700. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Study identification
- NCT ID
- NCT02195700
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- Auspex Pharmaceuticals, Inc.
- Industry
- Enrollment
- 117 participants
Conditions and interventions
Conditions
Interventions
- SD-809 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2014
- Primary completion
- Apr 30, 2015
- Completion
- Apr 30, 2015
- Last update posted
- Nov 8, 2021
2014 – 2015
United States locations
- U.S. sites
- 32
- U.S. states
- 18
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Tuscaloosa | Alabama | — | — |
| Not listed | Anaheim | California | — | — |
| Not listed | Glendale | California | — | — |
| Not listed | Oceanside | California | — | — |
| Not listed | Orange | California | — | — |
| Not listed | San Bernardino | California | — | — |
| Not listed | San Diego | California | — | — |
| Not listed | Denver | Colorado | — | — |
| Not listed | New Haven | Connecticut | — | — |
| Not listed | Stamford | Connecticut | — | — |
| Not listed | Washington D.C. | District of Columbia | — | — |
| Not listed | Boca Raton | Florida | — | — |
| Not listed | Gainesville | Florida | — | — |
| Not listed | Lake City | Florida | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | Orlando | Florida | — | — |
| Not listed | Port Charlotte | Florida | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Baltimore | Maryland | — | — |
| Not listed | Minneapolis | Minnesota | — | — |
| Not listed | Kansas City | Missouri | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Albuquerque | New Mexico | — | — |
| Not listed | Asheville | North Carolina | — | — |
| Not listed | Durham | North Carolina | — | — |
| Not listed | Raleigh | North Carolina | — | — |
| Not listed | Cleveland | Ohio | — | — |
| Not listed | Philadelphia | Pennsylvania | — | — |
| Not listed | Charleston | South Carolina | — | — |
| Not listed | Memphis | Tennessee | — | — |
| Not listed | Fort Worth | Texas | — | — |
| Not listed | Salt Lake City | Utah | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02195700, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 8, 2021 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02195700 live on ClinicalTrials.gov.